Mayne Pharma Group Limited (ASX:MYX)
Australia · Delayed Price · Currency is AUD | Market Cap | 230.74M -37.6% |
| Revenue (ttm) | 408.10M +5.1% |
| Net Income | -93.84M |
| EPS | -1.19 |
| Shares Out | 81.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,124 |
| Average Volume | 586,362 |
| Open | 2.850 |
| Previous Close | 2.820 |
| Day's Range | 2.820 - 2.860 |
| 52-Week Range | 2.600 - 7.310 |
| Beta | 1.06 |
| RSI | 43.13 |
| Earnings Date | Feb 25, 2026 |
About Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and in... [Read more]
Financial Performance
In fiscal year 2025, Mayne Pharma Group's revenue was 408.10 million, an increase of 5.07% compared to the previous year's 388.40 million. Losses were -93.84 million, -46.14% less than in 2024.
Financial StatementsNews
Mayne Pharma to return to court to fight Cosette for failed bid costs
The Adelaide-based company faces pressure from shareholders to restore value after share price sank on a failed bid.
Mayne Pharma Group Limited (MAYNF) Shareholder/Analyst Call Transcript
Mayne Pharma Group Limited (MAYNF) Shareholder/Analyst Call January 28, 2026 6:00 PM ESTCompany ParticipantsBruce G.
ASX 200 LIVE: Banks weigh on ASX; Neuren soars on $US700m sales plan, Block falls
Morningstar says mining M&A to pick up; Neuren’s Daybue eyes $US700m global sales; building approvals surge in November; job vacancies decline; Mayne Pharma cuts board size. Follow live.
Mayne Pharma under earnings pressure after failed takeover deal
Mayne says it made just $11.5 million in underlying earnings from July to November compared to $22.4 million over the same period last year.
Termination of Proposed Acquisition of Mayne Pharma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma ...
Australia Blocks U.S.-Based Cosette's $387.2 Million Takeover of Mayne Pharma
Australia's government said it would block a $387.2 million takeover of Mayne Pharma by U.S. company Cosette Pharmaceuticals on national security grounds, citing a need to protect critical medical sup...
Australia blocks Cosette Pharmaceuticals bid to buy Mayne Pharma
Australia on Friday blocked a A$672 million ($433 million) buyout offer for Mayne Pharma from U.S. drugmaker Cosette Pharmaceuticals, citing national interest.
Chalmers all but kills Mayne Pharma takeover bid
Pharmaceutical giant Cosette looks set to win its long-running battle to back out of its $672 million bid for Mayne Pharma after Jim Chalmers intervened.
Australia's Mayne Pharma falls as treasurer considers blocking Cosette's $437 million bid
Australia's Mayne Pharma said on Friday it had received a letter from its potential acquirer, Cosette, indicating that the country's treasurer is considering blocking the A$672 million ($436.67 millio...
ASX 200 LIVE: Shares rise as gold miners rally; Origin slumps 5pc; Endeavour drops; Steadfast down 7pc Mayne Pharma tanks
Shares rise; Origin’s revenue drops; Mayne Pharma shares decline as investors bet on its takeover deal being dead; Steadfast plunges after its CEO stood aside pending an investigation. Follow live.
Cosette's attempt to drop $438 million Mayne Pharma deal denied by court
An Australian court has moved to prevent U.S. drugmaker Cosette Pharmaceuticals from abandoning its A$672 million ($437.6 million) acquisition of Mayne Pharma , the ASX-listed company said on Thursday...
ASX200 LIVE: ASX resets record high; real estate stocks, gold miners rip
Shares rise as jobs data ramps up rate cut bets; PolyNovo taps new CEO; Mayne Pharma jumps after court win; Entertainment Rewards rockets 900pc. Follow live.
Court rules US giant can’t terminate Mayne Pharma takeover
Mayne Pharma took Cosette to court to enforce a $672 million takeover deal that the US giant tried to terminate. The court has ruled in Mayne’s favour.
Mayne Pharma director questioned management integrity, court hears
Mayne Pharma boss Shawn O’Brien was grilled in the NSW Supreme Court on the company’s financial forecasting, in proceedings brought by suitor Cosette.
Inside Mayne Pharma suitor’s battle to sink Project Crocodile
US healthcare giant Cosette alleges the Australian company should have known it could not meet earnings forecasts when it signed the deal in February.
Mayne Pharma says suitor’s plan to close factory is ‘not credible’
The ASX-listed healthcare business is trying to force its buyer to close on a $672 million deal, but the future of a plant in Adelaide is a major roadblock.
Mayne Pharma says no plans to close Adelaide factory
South Australian Premier Peter Malinauskas had expressed concern that takeover bidder Cosette had indicated a possible intention to close the plant.
Mayne Pharma, Cosette clash over Adelaide factory closure threat
South Australian Premier Peter Malinauskas had expressed concern that takeover bidder Cosette planned to close the plant.
ASX 200 live: Shares dip; Mayne Pharma craters 11pc on dialogue denial; Tourism Holdings exits Australian dealerships.
Shares dip; Mayne Pharma craters 11pc on dialogue denial; Mixi nabs PointBet; Tourism Holdings exits Australian dealerships.
Mayne Pharma Group Ltd (MAYNF) Full Year 2025 Earnings Call Highlights: Strong Women's Health ...
Mayne Pharma Group Ltd (MAYNF) Full Year 2025 Earnings Call Highlights: Strong Women's Health Performance Drives Revenue Growth
Full Year 2025 Mayne Pharma Group Ltd Earnings Call Transcript
Full Year 2025 Mayne Pharma Group Ltd Earnings Call Transcript
Mayne Pharma dodges questions on financial results
The Australian pharmaceuticals group, which is enmeshed in a court battle with former suitor Cosette Pharma, has narrowed its annual net loss to $93.8 million.
Jefferies, Mayne Pharma in spotlight in after suitor’s court win
American medicines giant Cosette has successfully sought confidential modelling which it says could prove that it was provided incomplete financial information.
Hedge fund bets US suitor won’t get out of Mayne Pharma takeover
Harvest Lane’s Ben Bailey says US-based Cosette will have to complete a multimillion-dollar acquisition of the Australian drug company.
Proxy advisers support Mayne Pharma deal as suitor tries to exit
US private equity backed pharmaceutical giant Cosette attempt to terminate its bid for Mayne Pharma is facing opposition from proxy advisers and activists.